ESR1 and neoplasm: We investigated genomic and transcriptomic differences between the MKShi/ERSlo subgroup and other ER+/HER2− tumours and examined markers that have been reported to predict benefit from CDK4/6i and immune checkpoint inhibitors (ICI).